

Zanubrutinib for treating chronic lymphocytic leukaemia

Information for the public

Published: 22 November 2023

www.nice.org.uk

Zanubrutinib (Brukinsa) is available on the NHS as a possible treatment for chronic lymphocytic leukaemia in adults if the leukaemia:

- is untreated, and there is:
 - a 17p deletion or tumour protein 53 mutation or
 - no 17p deletion or tumour protein 53 mutation, and fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab are unsuitable, or
- has been previously treated but the treatment has not worked well enough, or the leukaemia has come back.

If you are not eligible for zanubrutinib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on chronic lymphocytic leukaemia](#) may be a good place to find out more.

These organisations can give you advice and support:

- [CLL Support](#), 0800 977 4396
- [Leukaemia Care](#), 08088 010 444
- [Lymphoma Action](#), 0808 808 5555
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5528-2